secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001193125-24-100771
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva realigns reporting segments; Canada moved to International Markets from North America
--------------------------------------------------------------------------------

- Canada will be reported as part of International Markets segment, not North America, effective Q1 2024.
- Recast 2023 and 2022 segment data shows US segment revenue $7,731M (2023) and segment profit $2,394M.
- Canada 2023 revenue $393M, down 12.5% from $449M in 2022, included in International Markets.
- No impact on previously reported consolidated financial statements; prior periods restated for comparability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312524100771/0001193125-24-100771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312524100771/d800395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-100771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer